Clinic
Sisters of Charity Hospital of Buffalo New York
Sisters of Charity Hospital of Buffalo New York was paid $13.42M by Medicaid between Jan 2018 and Dec 2024, across 231 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 18% of everything it billed.
33Billing provider infoSISTERS OF CHARITY HOSPITAL OF BUFFALO NEW YORK
CHEEKTOWAGA, NY 14225
CHEEKTOWAGA, NY 14225
33aNPI1043455199assigned 12/03/2008
33bProvider typeCardiac Rehabilitation Clinic/Center
28Total paid$13.42M
24GClaims338,287
24DCodes billed231
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Cardiac Rehabilitation Clinic/Center providers in New York
Rank by total paid#3 of 5
Median peer was paid$13.42M
This provider vs. median1.0×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 1,598 | $33K | |
| 2019 | 30,225 | $974K | |
| 2020 | 46,769 | $1.55M | |
| 2021 | 45,335 | $1.75M | |
| 2022 | 72,469 | $2.93M | |
| 2023 | 79,079 | $3.42M | |
| 2024incomplete | 62,812 | $2.76M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 18% | 22,662 | 20,966 | $2.45M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 13,668 | 13,124 | $2.31M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 15% | 10,427 | 9,922 | $1.95M |
| 96361 | Intravenous infusion, hydration; each additional hour | 6.4% | 5,096 | 4,815 | $861K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 3.4% | 2,160 | 2,131 | $454K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 3.1% | 17,203 | 15,648 | $417K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.9% | 2,602 | 2,554 | $393K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 1,419 | 1,398 | $314K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 2.2% | 2,775 | 2,706 | $292K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.1% | 6,496 | 2,121 | $278K |
| 36415 | Collection of venous blood by venipuncture | 1.8% | 22,483 | 14,089 | $239K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 1.5% | 902 | 893 | $195K |
219 more codes
| 80053 | Comprehensive metabolic panel | 1.4% | 9,659 | $192K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 1.1% | 691 | $154K |
| 97161 | 1.1% | 2,136 | $149K | |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.0% | 2,316 | $139K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.0% | 3,458 | $138K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 3,178 | $133K |
| 87631 | <1% | 2,279 | $120K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 487 | $118K |
| G0378 | Hospital observation service, per hour | <1% | 104 | $114K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,006 | $113K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 369 | $111K |
| 93976 | <1% | 454 | $106K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 4,728 | $80K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 2,811 | $80K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,525 | $78K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 4,387 | $72K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 116 | $70K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 358 | $69K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 753 | $62K |
| C1776 | Joint device (implantable) | <1% | 12 | $51K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 836 | $46K |
| 90791 | Psychiatric diagnostic evaluation | <1% | 353 | $45K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,291 | $39K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,238 | $39K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 4,865 | $36K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,165 | $36K |
| 97803 | <1% | 961 | $31K | |
| 90670 | <1% | 1,650 | $29K | |
| 29581 | <1% | 163 | $29K | |
| 90686 | <1% | 1,216 | $28K | |
| 99406 | <1% | 913 | $27K | |
| 90648 | <1% | 1,622 | $27K | |
| 97010 | <1% | 2,119 | $27K | |
| 97802 | <1% | 757 | $26K | |
| 90715 | <1% | 1,187 | $24K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 719 | $23K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,698 | $23K |
| 83880 | <1% | 895 | $21K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 339 | $21K |
| 90723 | <1% | 1,237 | $21K | |
| 81025 | <1% | 6,985 | $18K | |
| 90633 | <1% | 1,029 | $18K | |
| 80061 | Lipid panel | <1% | 1,546 | $18K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 517 | $17K |
| 90734 | <1% | 919 | $16K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 762 | $15K |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | <1% | 278 | $15K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 245 | $14K |
| 90674 | <1% | 812 | $14K | |
| 90651 | <1% | 655 | $13K | |
| 99460 | <1% | 149 | $13K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 185 | $12K |
| 99201 | <1% | 113 | $12K | |
| 90680 | <1% | 688 | $11K | |
| 86850 | <1% | 365 | $10K | |
| 80076 | <1% | 1,341 | $10K | |
| 99238 | Hospital discharge day management, 30 minutes or less | <1% | 149 | $9K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 505 | $8K |
| 12001 | <1% | 24 | $8K | |
| 90677 | <1% | 316 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,990 | $7K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 19 | $7K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 92 | $7K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 2,817 | $7K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 35 | $7K |
| 83655 | <1% | 415 | $7K | |
| 99442 | <1% | 178 | $6K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 86 | $6K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,892 | $6K |
| 86900 | <1% | 402 | $6K | |
| 59425 | <1% | 71 | $6K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 12,207 | $6K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 4,675 | $6K |
| 93798 | <1% | 206 | $6K | |
| 86701 | <1% | 614 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,793 | $5K |
| 87481 | <1% | 152 | $5K | |
| 90710 | <1% | 302 | $5K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 242 | $5K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 4,052 | $4K |
| 99441 | <1% | 219 | $4K | |
| 90697 | <1% | 186 | $4K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 76 | $4K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 30 | $4K |
| 90707 | <1% | 224 | $4K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,639 | $4K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 333 | $4K |
| 76801 | <1% | 58 | $4K | |
| 90681 | <1% | 176 | $4K | |
| 90696 | <1% | 220 | $4K | |
| 90716 | <1% | 194 | $3K | |
| 87563 | <1% | 207 | $3K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 42 | $3K |
| 82607 | <1% | 681 | $3K | |
| M0247 | Intravenous infusion, sotrovimab, includes infusion and post administration monitoring | <1% | 12 | $3K |
| 93975 | <1% | 12 | $3K | |
| 90656 | <1% | 199 | $3K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,124 | $3K |
| 90714 | <1% | 172 | $3K | |
| 93971 | <1% | 67 | $3K | |
| 84439 | <1% | 529 | $3K | |
| 90620 | <1% | 162 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,034 | $3K |
| 99173 | <1% | 562 | $3K | |
| 90700 | <1% | 148 | $3K | |
| 90658 | <1% | 142 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 3,218 | $2K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 50 | $2K |
| 93041 | <1% | 540 | $2K | |
| 59426 | <1% | 20 | $2K | |
| 98968 | <1% | 65 | $2K | |
| 99000 | <1% | 81 | $2K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 28 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,810 | $2K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 63 | $2K |
| 87081 | <1% | 1,335 | $2K | |
| 81001 | <1% | 5,358 | $2K | |
| 73630 | <1% | 660 | $2K | |
| 76830 | Ultrasound, transvaginal | <1% | 87 | $1K |
| 73130 | <1% | 491 | $1K | |
| 70486 | <1% | 12 | $1K | |
| 86901 | <1% | 84 | $1K | |
| 85610 | <1% | 2,209 | $1K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 44 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,296 | $1K |
| 84484 | <1% | 5,119 | $1K | |
| 90657 | <1% | 64 | $1K | |
| 82803 | <1% | 53 | $1K | |
| 82948 | <1% | 1,317 | $1K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,014 | $1K |
| 85027 | <1% | 1,328 | $955.27 | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 57 | $951.80 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 1,199 | $934.04 |
| 73030 | <1% | 303 | $892.83 | |
| 72110 | <1% | 122 | $854.34 | |
| 87660 | <1% | 1,624 | $799.72 | |
| 73562 | <1% | 183 | $762.82 | |
| 97165 | <1% | 12 | $717.14 | |
| 81513 | <1% | 630 | $714.06 | |
| 90732 | <1% | 16 | $597.95 | |
| 85730 | <1% | 2,211 | $586.25 | |
| 83690 | <1% | 4,959 | $571.20 | |
| 84702 | <1% | 566 | $497.68 | |
| 85018 | <1% | 414 | $471.25 | |
| 83735 | <1% | 1,965 | $457.42 | |
| 98967 | <1% | 15 | $432.57 | |
| 86580 | <1% | 87 | $430.00 | |
| 85379 | <1% | 1,245 | $386.30 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 918 | $369.20 |
| 73610 | <1% | 366 | $351.83 | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 19 | $318.02 |
| 81002 | <1% | 774 | $317.52 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,053 | $267.69 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,694 | $240.99 |
| 81003 | <1% | 2,907 | $219.65 | |
| 73564 | <1% | 156 | $218.85 | |
| 90461 | <1% | 1,510 | $213.91 | |
| 87077 | <1% | 1,056 | $204.28 | |
| 82746 | <1% | 90 | $188.95 | |
| 72100 | <1% | 25 | $168.12 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,440 | $160.14 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,736 | $152.70 |
| 87070 | <1% | 143 | $151.76 | |
| 82150 | <1% | 1,164 | $144.02 | |
| 85007 | <1% | 712 | $139.67 | |
| 87186 | <1% | 769 | $114.24 | |
| 85652 | <1% | 80 | $78.64 | |
| 83605 | <1% | 503 | $75.41 | |
| 72050 | <1% | 12 | $63.21 | |
| 86803 | <1% | 108 | $52.85 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 988 | $52.11 |
| 73502 | <1% | 12 | $50.52 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 110 | $47.62 |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 520 | $47.55 |
| 83550 | <1% | 44 | $47.16 | |
| 74018 | <1% | 25 | $46.58 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 978 | $44.21 |
| 82728 | <1% | 12 | $43.00 | |
| 87510 | <1% | 75 | $32.73 | |
| 87480 | <1% | 75 | $32.73 | |
| 87040 | <1% | 412 | $32.50 | |
| 95806 | <1% | 51 | $30.57 | |
| 73140 | <1% | 12 | $30.11 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 35 | $30.09 |
| J3490 | Unclassified drugs | <1% | 586 | $29.57 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 411 | $28.34 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,239 | $28.05 |
| 85014 | <1% | 12 | $24.30 | |
| 73110 | <1% | 28 | $22.74 | |
| 87590 | <1% | 175 | $20.50 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,315 | $18.21 |
| 73620 | <1% | 14 | $18.00 | |
| 74019 | <1% | 16 | $16.58 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 994 | $13.25 |
| 88312 | <1% | 43 | $13.18 | |
| J2704 | Injection, propofol, 10 mg | <1% | 387 | $11.16 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 654 | $5.65 |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 71 | $5.32 |
| 86308 | <1% | 30 | $4.73 | |
| 81015 | <1% | 197 | $2.70 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 30 | $2.28 |
| 87205 | <1% | 106 | $1.57 | |
| A9270 | Non-covered item or service | <1% | 8,318 | $1.05 |
| 96376 | 0% | 174 | $0.00 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | 0% | 268 | $0.00 |
| J1790 | Injection, droperidol, up to 5 mg | 0% | 54 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 14 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 17 | $0.00 |
| 86403 | 0% | 13 | $0.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | 0% | 130 | $0.00 |
| 90474 | 0% | 64 | $0.00 | |
| J0132 | Injection, acetylcysteine, 100 mg | 0% | 114 | $0.00 |
| 99080 | 0% | 794 | $0.00 | |
| 99152 | 0% | 133 | $0.00 | |
| G0500 | Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) | 0% | 28 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 47 | $0.00 |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 26 | $0.00 |
| 87339 | 0% | 14 | $0.00 | |
| 73080 | 0% | 18 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMACHOLZ, DAVID (CFO)
Parent organizationSISTERS OF CHARITY HOSPITAL
| Provider | Location | Paid |
|---|---|---|
| Mercy Hospital of Buffalo | Buffalo, NY | $29.86M |
| Mount ST. Mary's Hospital of Niagara Falls | Lewiston, NY | $22.19M |
| Sisters of Charity Hospital of Buffalo New York | Buffalo, NY | $3.93M |
| Mount ST. Mary's Hospital of Niagara Falls | Lewiston, NY | $2.87M |
| Mercy Hospital of Buffalo | Buffalo, NY | $449K |
| Kenmore Mercy Hospital | Kenmore, NY | $70K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.